|
|
Post by akemp3000 on May 6, 2024 4:56:44 GMT -5
The real needle mover is Afrezza and its so huge most cant see it like seeing the forest for the trees but its still moving. Glad to see not everyone has given up the hopium.  Maybe you need to pass the hopium pipe to MNKD management. Their released guidance for Afrezza revenue is rather lackluster going all the way out to 2030. It's not where they expect the majority of our growth will come. Maybe you're right and they are wrong. It would be foolish for MNKD management to release optimistic guidance based the highly anticipated FDA approval of Afrezza for pediatrics before its happened, not to mention other related expectations for management possibly even including a partnership. This doesn't mean management's expectations don't align with letitride. Letitride simply has the luxury of expressing the optimism first. Management's current position aligns nicely with the phrase, "Under promise and over deliver". While management hasn't done this with Afrezza and the pps to date, IMO, they likely still anticipate it happening, otherwise they would have gone in another direction. |
|
|
|
Post by letitride on May 6, 2024 8:28:18 GMT -5
I believe there are many that dont realize the relevance of (it changed my life) by type 1 diabetics that want to live life more human. Its happening!
|
|
|
|
Post by ktim on May 6, 2024 15:34:22 GMT -5
Glad to see not everyone has given up the hopium. Maybe you need to pass the hopium pipe to MNKD management. Their released guidance for Afrezza revenue is rather lackluster going all the way out to 2030. It's not where they expect the majority of our growth will come. Maybe you're right and they are wrong. It would be foolish for MNKD management to release optimistic guidance based the highly anticipated FDA approval of Afrezza for pediatrics before its happened, not to mention other related expectations for management possibly even including a partnership. This doesn't mean management's expectations don't align with letitride. Letitride simply has the luxury of expressing the optimism first. Management's current position aligns nicely with the phrase, "Under promise and over deliver". While management hasn't done this with Afrezza and the pps to date, IMO, they likely still anticipate it happening, otherwise they would have gone in another direction. There I thought they had gone in a different direction. But glad for the clarification on what management is really thinking. I'm not the type that is good at long distance mind reading. Who is the partnership going to be with? That was such a fun topic in past years. |
|
